Pharmaceutical country profile





Socioeconomic



Population¹

281 603 800 (2025)



Life expectancy at birth²

73.4 years (2023)



GDP/capita (current US\$)3


US\$ 4876.3 (2023)



Spending on health

Current health expenditure (CHE)/capita (current US\$)4

US\$ 127 (2022)



2.69% (2022) Current health expenditure as share of GDP⁴



51.76% (2022) Government health expenditure (% of CHE)⁴

32.96% (2022) Out-of-pocket expenditure (% of CHE)⁴



Spending on pharmaceuticals

Government pharmaceutical expenditure

No data

Government pharmaceutical expenditure/capita

No data







Medical and pharmacy workforce

Medical doctors/ 10 000 population⁶

7.3 (2024)

Pharmacists/ 10 000 population⁶

7 (2024)

Pharmacy education accreditation

Yes

Continuing professional development for pharmacists

Yes



Pharmaceutical legislation and policy

2006 National Medicines Policy

2017-2019

National Action Plan for AMR

2021

NEML, Ministry of Health Decree HK.01.07/Menkes/6477/2021; National Formulary, KMK HK.01.07/Menkes/6485/2021

2022

National Formulary, KMK HK.01.07/Menkes/1970/2022

2023


Health Law 17/2023; National Formulary and NEML, Ministry of Health Decree HK.01.07/MENKES/2197/2023

2024

Government Regulation 28/2024

2025-2029

National Strategy for Antimicrobial Resistance in Human Health Sector



National Medicines Quality Control Laboratory

✓ ISO 17025 certified9

WHO prequalified9

Rational selection



Body responsible for selection of medical products¹

Ministry of Health

✓ HTA used in the selection process

✓ NEML incorporated AWaRE list ✓ Medicines listed by level of care

✓ Traditional medicines included

National Essential Medicines List (number of active ingredient)¹⁰

1980-2008 2011 2013 2015 2017 2019 2021 2023 9 revisions; 323 medicines 331 medicines 324 medicines 319 medicines 324 medicines 318 medicines 320 medicines 623 APIs; 1,59 SKUs

National Medicines Formulary¹⁰

2013 2015 2017 2019 2021 2022

National Essential Diagnostics List¹⁰: No

Purchasing



Public sector

✓ Procurement: Decentralized

Agency responsible for procurement: Ministry of Health and National Public Procurement Agency (LKPP) as regulator; facilities will do the procurement

LMIS used: No data

Frequency of tender: No specific timeline/frequency

✓ Social Health Insurance

Name of SHI scheme: Jaminan Kesehatan Nasional (JKN); SHI for all population where BPJS Kesehatan as the operational agency

Population coverage: 278 467 057 participants, 98.8% of the Indonesian population

Number of products covered: No data

Pricing regulation



Pricing regulatory authority9

Ministry of Health

Public sector

Tendering¹⁰: Yes

Private sector

Maximum retail price: Yes

Number of price controlled products: MRP is applied for all registered products

2015

Ministry of Health decree 98/2015

2024

Ministry of Health decree, HK.01.07/ MENKES/503/2024

Market distribution

Estimated pharmaceutical market value

No data



Tertiary hospitals¹¹: 70 Secondary hospitals¹¹: 3085 PHC facilities¹¹: 10 180 **Private**

Manufacturers¹²: 241 Importers: No data

Wholesellers/distributors¹¹: 2930 Retail pharmacies¹¹: 31 955

Market exit



Legal provision for

- ✓ Cancellation of licences of pharmaceutical establishments
- ✓ Cancellation of marketing authorization of products
- ☑ Initiating product recalls and withdrawals

References

- 1. The Statistics Indonesia, https://www.bps.go.id/id/statistics-table/2/MTk3NSMy/jumlah-penduduk-pertengahan-tahun.html, accessed 12 April 2025.
- 2. Badan Pusat Statistik Indonesia. (28 Februari 2023). Statistik Indonesia 2023. Diakses pada 10 Maret 2025, https://www.bps.go.id/id/publication/2023/02/28/18018f9896f09f03580a614b/statistik-indonesia-2023.html, accessed 2 February, 2025.
- 3. World Bank, GDP per capita, https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=ID, accessed 23 July 2025.
- 4. World Health Organization, Global Health Expenditure database, Domestic General Government Health Expenditure as % of CHE, https://www.who.int/data/gho, accessed 15 August 2025.
- 5. Indonesia National Health Accounts (NHA) Report 2021.
- 6. World Health Organization, Regional Office for South-East Asia, Monitoring progress on universal health coverage and the health-related Sustainable Development Goals in the South-East Asia Region 2024 update, https://www.who.int/publications/i/item/9789290229636., accessed 22 August 2025.
- 7. World Health Organization, Global Antimicrobial Resistance and Use Surveillance System (GLASS), https://www.who.int/initiatives/glass/country-participation, accessed 15 August 2025.
- 8. Badan Pengawas Obat dan Makanan, Annual Report 2023, https://www.pom.go.id/kinerja/laporan-tahunan-4, accessed 11 April, 2024.
- 9. World Health Organization. Regional Office for South-East Asia. (2021). Access to medical products in the South-East Asia Region, 2021: Review of progress. World Health Organization. Regional Office for South-East Asia. https://www.who.int/publications/i/item/9789290228967.12., accessed 25 August 2025.
- 10. Reported by the Ministry of Health, Indonesia, 2023 (internal communication)
- 11. Indonesia Health Profile 2023, Ministry of Health, https://kemkes.go.id/eng/indonesia-health-profile-2023, accessed 9 August 2025.
- 12. Badan Pengawas Obat dan Makanan, LAPORAN KINERJA BPOM 2024, https://www.pom.go.id/storage/sakip/Laporan%20Kinerja%20 BPOM%20Tahun%202024.pdf, accessed 25 August 2025.